SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: Art Vandelay AIA who wrote (3232)6/7/1999 12:15:00 AM
From: IRWIN JAMES FRANKEL  Read Replies (1) | Respond to of 10280
 
Xopenex

Once Xopenex:
is available in all forms and dosages,
is priced proportionately to the nebulized form already on the market,
and if it demonstrates that it does not produce reduced FEV1 and that genetic does reduce FEV1;

What share of the $2.4 billion worldwide market will Xopenex capture?

I realize that this question calls for a rather speculative answer but would appreciate others thoughts.

ij